Taysha IPO Presentation Deck
Our three distinct franchises have the potential
to address over half a million patients (US+EU)
500,000
Estimated Patient Population (US + EU)
SURF1
= 350
Neurodegenerative
W
CLN1
= 600
wwwwwwww
Lafora
= 700
APBD
= 1000
GSDs
= 20,000
Tauppathies¹
= 40,000
FOXGI
* 20,000
Neurodevelopmental
Rett
syndrome
= 25,000
Angelman
Syndrome
= 30,000
Prader-Willi
+ 40,000
Fragile X
syndrome
= 96,000
Additional
Programs
- 200,000
Genetic Epilepsy
SLC1345
SLC6A1
= 16,000
KCNQZ
= 17,000
TAYSHA
||||| GENE THERAPIES
"Tauopathies only include MAPT-FTD, PSP, CBD. In addition, Taysha intends to pursue
development of our MAPT program in subpopulations of patients with Alzheimer's Disease
Additional programs include TSHA-107, TSHA-108 and TSHA-109View entire presentation